Modality
ERT
MOA
SGLT2i
Target
HER2
Pathway
RNA Splicing
IPFTTR Amyloidosis
Development Pipeline
Preclinical
~Aug 2022
→ ~Nov 2023
Phase 1
Feb 2024
→ Jun 2031
Phase 1Current
NCT04972910
1,561 pts·IPF
2024-02→2031-06·Terminated
1,561 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-06-145.2y awayInterim· IPF
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P1
Termina…
Catalysts
Interim
2031-06-14 · 5.2y away
IPF
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04972910 | Phase 1 | IPF | Terminated | 1561 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 | |
| ELV-1411 | Enliven | NDA/BLA | HER2 |